[go: up one dir, main page]

BR112022025227A2 - Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit - Google Patents

Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit

Info

Publication number
BR112022025227A2
BR112022025227A2 BR112022025227A BR112022025227A BR112022025227A2 BR 112022025227 A2 BR112022025227 A2 BR 112022025227A2 BR 112022025227 A BR112022025227 A BR 112022025227A BR 112022025227 A BR112022025227 A BR 112022025227A BR 112022025227 A2 BR112022025227 A2 BR 112022025227A2
Authority
BR
Brazil
Prior art keywords
deliver
conjugates
conjugate
short peptide
increase
Prior art date
Application number
BR112022025227A
Other languages
English (en)
Inventor
Binder Whitney
D Blanchette Craig
A Darwish Martine
Hannoush Rami
Gao Xinxin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112022025227A2 publication Critical patent/BR112022025227A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONJUGADOS, COMPOSIÇÃO FARMACÊUTICA, FORMULAÇÃO LÍQUIDA, MÉTODOS PARA PREPARAR UM CONJUGADO, PARA AUMENTAR A ESTABILIDADE, PARA TRATAR UM INDIVÍDUO, PARA ENTREGAR UM POLIPEPTÍDEO DE LIGAÇÃO, PARA ENTREGAR UM PEPTÍDEO CURTO, PARA ENTREGAR UM AGENTE BIOLOGICAMENTE ATIVO, MÉTODO PARA REDUZIR A CONJUGAÇÃO LIPÍDIO-PROTEÍNAESQUELETO E MÉTODO PARA AUMENTAR A ATIVIDADE BIOLÓGICA, USO DO CONJUGADO E SISTEMA OU KIT. A presente invenção refere-se, em geral, a conjugados de partículas nanolipoproteicas que compreendem pelo menos um polipeptídeo e conjugados de partículas nanolipoproteicas que compreendem pelo menos um peptídeo curto entre 20-60 aminoácidos de comprimento. Também são fornecidas composições e sistemas relacionados e métodos de preparação e uso dos mesmos. Em particular, são fornecidos conjugados de partículas de nanolipoproteína (NLP) com fragmentos de ligação ao antígeno (Fabs), em que a NLP compreende uma bicamada de lipídios formadores de membrana circundados por proteínas-esqueleto e os Fabs são conjugados a uma ou ambas as superfícies de bicamada. Em algumas modalidades, os conjugados (NLP) compreendem ainda um peptídeo curto de 20-60 aminoácidos de comprimento. Os conjugados e as composições e sistemas relacionados geralmente mostram boa estabilidade e capacidade de fabricação, retêm a atividade de ligação ao antígeno e podem aumentar a potência de ligação ao antígeno, fornecendo plataformas versáteis para a entrega de Fab e terapias e diagnósticos baseados em Fab, bem como fornecendo estabilidade plataformas para distribuição de outros agentes terapêuticos e/ou de diagnóstico.
BR112022025227A 2020-06-11 2021-06-10 Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit BR112022025227A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038075P 2020-06-11 2020-06-11
US202163151591P 2021-02-19 2021-02-19
PCT/US2021/036878 WO2021252803A1 (en) 2020-06-11 2021-06-10 Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same

Publications (1)

Publication Number Publication Date
BR112022025227A2 true BR112022025227A2 (pt) 2023-01-03

Family

ID=76744974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025227A BR112022025227A2 (pt) 2020-06-11 2021-06-10 Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit

Country Status (12)

Country Link
US (1) US20240059755A1 (pt)
EP (1) EP4164693A1 (pt)
JP (1) JP2023529203A (pt)
KR (1) KR20230023727A (pt)
CN (1) CN115803063A (pt)
AU (1) AU2021289738A1 (pt)
BR (1) BR112022025227A2 (pt)
CA (1) CA3183808A1 (pt)
IL (1) IL298878A (pt)
MX (1) MX2022015651A (pt)
TW (1) TW202214307A (pt)
WO (1) WO2021252803A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3253551A1 (en) * 2022-05-13 2023-11-16 Kisbee Therapeutics, Inc. APOE LIPOPROTEIN SYSTEMS
WO2024258229A1 (ko) * 2023-06-15 2024-12-19 알엔에이진(주) 아포지질단백질 또는 이의 단편을 포함하는 융합 단백질 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
WO2009143280A2 (en) * 2008-05-22 2009-11-26 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions, methods and systems
US20150297675A1 (en) 2012-08-28 2015-10-22 Aaron Osborne Use of a vegf antagonist in treating ocular vascular proliferative diseases
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
EP3426304A4 (en) 2016-03-07 2019-11-27 Lawrence Livermore National Security, LLC NANOLIPOPROTEIN PARTICLES AND ASSOCIATED COMPOSITIONS AND SYSTEMS FOR IMPROVED ACTIVE LOADING
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11491215B2 (en) * 2018-05-24 2022-11-08 Lawrence Livermore National Security, Llc Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Also Published As

Publication number Publication date
AU2021289738A1 (en) 2022-12-15
JP2023529203A (ja) 2023-07-07
IL298878A (en) 2023-02-01
WO2021252803A1 (en) 2021-12-16
EP4164693A1 (en) 2023-04-19
MX2022015651A (es) 2023-01-16
CN115803063A (zh) 2023-03-14
CA3183808A1 (en) 2021-12-16
KR20230023727A (ko) 2023-02-17
US20240059755A1 (en) 2024-02-22
TW202214307A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
US11696892B2 (en) Lipid nanoparticles for delivering modified RNA encoding a VEGF-A polypeptide
JP7495150B2 (ja) 局所エリスロポエチン製剤および前記製剤を用いて創傷治癒を改善するための方法および前記製剤の美容用途
AU2005294805B2 (en) A mixture for transdermal delivery of low and high molecular weight compounds
ES2617063T3 (es) Composición de vesículas lipídicas bifásicas y método para tratar la displasia de cuello uterino por suministro intravaginal
CN104884065B (zh) 治疗癌症的方法
ES2594896T3 (es) Preparaciones combinadas con un antagonista de citocina y un corticoesteroide
Hammers et al. Controlled release of IGF‐I from a biodegradable matrix improves functional recovery of skeletal muscle from ischemia/reperfusion
EP3247398A1 (en) Lipid nanoparticle compositions
HRP20141251T1 (hr) Ekstracelularna hijaluronidaza iz streptomyces koganeiensis
Chen et al. In vivo targeted delivery of ANGPTL8 gene for beta cell regeneration in rats
SG186607A1 (en) Protein formulations and methods of making same
NZ206728A (en) Pharmaceutical compositions containing calcitonin and a surface active agent
BR112022025227A2 (pt) Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit
NZ543646A (en) C1 inhibitor with short half-life for transient treatment
Ostróżka-Cieślik The potential of pharmaceutical hydrogels in the formulation of topical administration hormone drugs
EP1765310B1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
US20180169191A1 (en) Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
Luft et al. Experimental aminoglycoside nephrotoxicity: accomplishments and future potential
US20220226243A1 (en) Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same
Gerber et al. Prolongation of murine cardiac allograft survival by microspheres containing TNFα and IL1-β neutralizing antibodies
ES2912162T3 (es) Composiciones de insulina de acción rápida
JP7636812B2 (ja) 創傷治癒を促進するための組成物および方法
CN107753953A (zh) 聚乙二醇化激肽原酶的制剂及其应用
Tian et al. Recombinant ApoE3 corona plus sucrose vitrification endows mRNA-LNPs with Freeze–Thaw and− 80° C stability
US20210023236A1 (en) Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues